Dai Jun, Chen Zhaojun, Wang Shixuan, Xia Fan, Lou Xiaoding
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
State Key Laboratory of Biogeology and Environmental Geology, Faculty of Materials Science and Chemistry, China University of Geosciences, Wuhan, 430074, China.
Mater Today Bio. 2022 May 5;15:100279. doi: 10.1016/j.mtbio.2022.100279. eCollection 2022 Jun.
Erythrocytes are often used for the development of cell membrane camouflaged nanoparticles (NPs) due to their wide range of sources. However, whether the difference between autologous and allogeneic sources for the erythrocyte membranes have an influence on the performance of camouflaged NPs, which is still inconclusive. To this end, we developed two aggregation-induced emission (AIE) photosensitizers camouflaged with erythrocyte membranes (E-M), named E-M@P and E-M@P, which were prepared using autologous- and allogeneic-derived erythrocytes, respectively. In vivo, E-M@P-mediated photodynamic therapy (PDT) effectively inhibited tumor growth, and this therapeutic effect did not differ between E-M@P and E-M@P. Importantly, there were no differences between E-M@P and E-M@P treated mice in terms of general condition, organ function or immune system. Both E-M@P and E-M@P have been shown not to cross the placental barrier and do not affect the development of the embryo, which could be a good platform for the treatment of pregnancy-related disorders. These findings provided more detailed evidences for erythrocyte membrane camouflaged NPs as a promising therapeutic platform, since there is no difference in efficacy or biosafety of either autologous or allogeneic erythrocyte-derived NPs.
由于红细胞来源广泛，其常被用于制备细胞膜伪装的纳米颗粒（NPs）。然而，红细胞膜的自体来源和异体来源之间的差异是否会对伪装纳米颗粒的性能产生影响，目前尚无定论。为此，我们制备了两种分别用自体和异体来源红细胞膜（E-M）伪装的聚集诱导发光（AIE）光敏剂，命名为E-M@P和E-M@P。在体内，E-M@P介导的光动力疗法（PDT）有效抑制了肿瘤生长，且E-M@P和E-M@P之间的治疗效果没有差异。重要的是，在一般状况、器官功能或免疫系统方面，E-M@P和E-M@P处理的小鼠之间没有差异。E-M@P和E-M@P均未穿过胎盘屏障，也不影响胚胎发育，这使其有望成为治疗妊娠相关疾病的良好平台。这些发现为红细胞膜伪装的纳米颗粒作为一种有前景的治疗平台提供了更详细的证据，因为自体或异体红细胞来源的纳米颗粒在疗效或生物安全性方面没有差异。
